Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
67.20    -0.80 (-1.18%)
Bid:
67.10
Ask:
67.30
Spread: 0.20 (0.298%)
Market Cap: £593.66m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Board changes

6 Oct 2021 07:00

RNS Number : 1257O
IP Group PLC
06 October 2021
 

FOR RELEASE ON

06 October 2021

 

 

IP Group plc - Board changes

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), the developer of intellectual property-based businesses, announces that following the successful flotation of the Group's largest holding, Oxford Nanopore Technologies plc, Alan Aubrey, Chief Executive Officer, and Mike Townend, Chief Investment Officer, are retiring and stepping down from the IP Group Board from today.

 

The Board is delighted to announce that Greg Smith, Chief Financial Officer, will succeed Alan as Chief Executive Officer and David Baynes, the Group's Chief Operating Officer, will take on executive responsibility for finance and becomes Chief Financial and Operating Officer.

 

To facilitate an orderly handover and transition, both Alan and Mike will remain as employees, serving their six-month notice periods until 06 April 2022 and as consultants for a minimum of 12 months from 07 April 2022.

 

As referenced in the Group's 2020 Annual Report & Accounts, the Nomination Committee used an external executive search and leadership consultancy to assist in identifying and assessing candidates both internally and externally as part of succession planning. The Committee deferred finalising its recommendation to align the final decision with anticipated events in the portfolio, such as the potential Oxford Nanopore flotation, and to ensure continued stability for the Group during the pandemic. Following the flotation of Oxford Nanopore and the easing of COVID-19 restrictions, the Committee reconvened and its recommendations were unanimously accepted by the Board.

 

Sir Douglas Flint, Chairman of IP Group, said: "On behalf of the Board and the wider IP Group family, I would like to thank both Alan and Mike for the transformational contributions they have made to IP Group over the past 16 and 14 years respectively. During Alan's tenure as CEO, the value of the portfolio has increased more than 28-fold to over £1.2bn* and has produced several companies worth more than £1bn. We are delighted that Greg will step into the role of CEO and lead the Group in its next phase. We are also pleased that Alan and Mike will continue with the Group in a consulting capacity so that the Group can continue to call on their significant experience in the sector. Greg has more than 20 years' experience in financial services, having been in the role of CFO for more than ten years and with IP Group for more than thirteen years. He has played a central role in developing and executing the Group's growth strategy which made him the obvious and unanimous choice to succeed Alan."

 

Alan Aubrey said: "Following the successful flotation of Oxford Nanopore Technologies on the London Stock Exchange, this felt a natural moment to step back. It has been a privilege and an honour to build and lead the team at IP Group and I am proud of all that has been achieved during this time. The Group is in great shape with a strong balance sheet, a portfolio of exciting growth technology companies and opportunities and I am confident that it will go from strength to strength under Greg's leadership. I look forward to continuing working with IP Group in a different capacity going forward and continuing to support the team in the future."

 

Commenting on his new role, Greg Smith said: "It is an exciting time to be taking on the role of CEO at IP Group. The Group benefits from a very strong financial position, a portfolio of growth technology companies and an excellent pipeline. I am looking forward to building on recent successes and I am confident that IP Group will continue to deliver world-changing businesses that have real impact as well as deliver value for all stakeholders."

 

The Group will consult with shareholders this Autumn on remuneration arrangements for the CEO and CFOO as part of the regular triennial review of Directors remuneration policy. IP Group will continue to align the interests of the Executive team with those of shareholders and other stakeholders and will discuss the optimum structure and level required to achieve this as part of the forthcoming consultation. Remuneration arrangements for the departing executive directors will be published on the Company's website and included in the 2021 Annual Report in the usual way.

There are no further updates required under Listing Rule 9.6.13 as a result of this change of roles.

*As at 30 June 2021.

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7979 853802

Charlotte Street Partners

David Gaffney

+44 (0) 7854 609998

Andrew Wilson

+44 (0) 7810 636995

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

Group holdings in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAVELFBFBLEFBD
Date   Source Headline
26th Mar 202112:26 pmRNSEMA positive opinion for Diurnal's Chronocort
10th Mar 20217:00 amRNSAnnual Results
4th Mar 20216:07 pmRNSHolding(s) in Company
2nd Mar 202112:03 pmRNSHolding(s) in Company
24th Feb 202110:33 amRNSNotice of Results
18th Feb 20214:31 pmRNSHolding(s) in Company
18th Feb 20218:00 amRNSHolding(s) in Company
17th Feb 20217:00 amRNSPortfolio company ApcinteX acquired by Centessa
10th Feb 20217:00 amRNSIP Group, Inc. raises $50.0m (£36.5m*) of funding
9th Feb 20213:52 pmRNSHolding(s) in Company
2nd Feb 20215:15 pmRNSHolding(s) in Company
11th Jan 20215:29 pmRNSHolding(s) in Company
6th Jan 20214:57 pmRNSPortfolio co Hinge Health completes $300m round
6th Jan 202111:34 amRNSHolding(s) in Company
6th Jan 20217:00 amRNSPortfolio co Oxbotica completes £36m funding round
4th Dec 202011:41 amRNSHolding(s) in Company
3rd Dec 20208:01 amRNSArtios and Merck in global strategic collaboration
25th Nov 20207:00 amRNSDirector Declaration
23rd Nov 20205:05 pmRNSHolding(s) in Company
21st Oct 20207:00 amRNSInvestor webinar
13th Oct 20207:00 amRNSOxford Nanopore funding round and contract win
9th Oct 20209:46 amRNSOxford Nanopore's LamPORE test gains CE-IVD mark
7th Oct 20207:00 amRNSEnterprise Therapeutics' program acquired by Roche
23rd Sep 20201:40 pmRNSHolding(s) in Company
15th Sep 202012:07 pmRNSSecond Price Monitoring Extn
15th Sep 202012:02 pmRNSPrice Monitoring Extension
7th Sep 202012:07 pmRNSSecond Price Monitoring Extn
7th Sep 202012:02 pmRNSPrice Monitoring Extension
1st Sep 20205:18 pmRNSForm 8.3 - Modern Water plc
5th Aug 20207:00 amRNSHalf-yearly results
3rd Aug 20207:00 amRNSNanopore partners with govt on covid-19 test
30th Jul 202012:08 pmRNSSecond Price Monitoring Extn
30th Jul 202012:02 pmRNSPrice Monitoring Extension
29th Jul 20209:45 amRNSHolding(s) in Company
28th Jul 20202:44 pmRNSNotice of Results
14th Jul 20201:29 pmRNSIP Group sells 9.16m shares in Ceres Power
14th Jul 20207:00 amRNSResult of secondary placing in Ceres Power
13th Jul 20205:11 pmRNSProposed secondary placing in Ceres Power Holdings
6th Jul 202012:02 pmRNSPrice Monitoring Extension
6th Jul 20207:00 amRNSAppoints Prof. Clark Chair of ESG Ethics Committee
3rd Jul 202012:07 pmRNSSecond Price Monitoring Extn
3rd Jul 202012:02 pmRNSPrice Monitoring Extension
24th Jun 20202:39 pmRNSHolding(s) in Company
24th Jun 20208:10 amRNSHolding(s) in Company
23rd Jun 202011:37 amRNSLTIP & DBSP awards; Director/PDMR shareholding
18th Jun 20202:05 pmRNSResult of AGM
18th Jun 20207:00 amRNSAGM Statement
9th Jun 20205:47 pmRNSAGM update
5th Jun 20206:28 pmRNSHolding(s) in Company
26th May 202010:05 amRNSInivata receives $25m investment from NeoGenomics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.